Related Experiment Videos
Elevated thrombotic activity after myocardial infarction: A 2-year follow-up study
V Martínez-Sales1, V Vila, E Réganon
1Research Center, Department of Clinic Pathology, La Fe University Hospital, Valencia, Spain.
This study looked at how blood clotting activity changes in patients who had a heart attack and were treated with aspirin for two years. Researchers collected blood samples from ten patients at nine different time points after the heart attack. They measured several clotting-related markers, including fibrinogen, fibrinopeptide A, and prothrombin fragments. At the start of the study, most of these markers were significantly higher than normal. While some markers returned to normal levels within a few months, others like fibrinopeptide A and prothrombin fragments stayed elevated for the entire two-year period. This suggests that blood clotting activity remains high for a long time after a heart attack, even with aspirin treatment. The study also found that tissue factor levels did not change much over time. These findings indicate that aspirin may not fully restore normal clotting function in the long term. The results could help guide future treatment strategies for heart attack survivors.
Area of Science:
- Cardiovascular disease research within clinical hematology
- Thrombosis and hemostasis in post-myocardial infarction care
Background:
Prior research has established that myocardial infarction (MI) triggers acute changes in coagulation markers. However, the long-term persistence of these changes remains unclear. While it is known that fibrinogen and thrombin levels rise immediately after MI, the trajectory of these markers over extended periods is less documented. Existing studies often focus on short-term outcomes, leaving a gap in understanding how coagulation activity evolves in the months and years following MI. This uncertainty drives the need for longitudinal studies that track thrombotic activity beyond the acute phase. The role of aspirin in modulating these markers is also not fully understood. No prior work had resolved whether elevated thrombin generation persists for years after MI. The significance of this gap is that it affects long-term risk assessment and treatment strategies for MI survivors. Understanding the timeline of coagulation normalization could improve secondary prevention approaches. This study aims to address these uncertainties by examining thrombotic activity over a two-year period.
Purpose Of The Study:
The aim of this research is to investigate how thrombotic activity evolves in patients who have experienced a myocardial infarction and are receiving aspirin therapy. The specific problem addressed is the lack of data on how long elevated coagulation markers persist after MI. The motivation stems from the clinical need to understand whether aspirin treatment can normalize these markers over time. By tracking multiple coagulation parameters over two years, the study seeks to determine if a hypercoagulable state remains after MI. The study focuses on fibrinogen, fibrinopeptide A, prothrombin fragments, and other relevant markers. The goal is to assess whether elevated levels are transient or persistent. This information could inform long-term antithrombotic therapy decisions. The study's contribution lies in its longitudinal design and detailed marker analysis.
Main Methods:
The study followed ten MI patients receiving aspirin (200 mg/day) for two years. Blood samples were collected at nine time points: 7, 30, 60, 90, 120, 150, 180, 360, and 720 days post-MI. Researchers measured plasma levels of fibrinogen (Fg), high molecular weight fibrinogen (HMW-Fg), fibrinopeptide A (FPA), prothrombin fragment 1+2 (F1+2), beta-thromboglobulin (beta-TG), von Willebrand factor (vWF), tissue factor (TF), and TF pathway inhibitor (TFPI). These markers were compared to normal reference ranges. The study used standardized laboratory techniques for quantification. Time points were selected to capture acute, subacute, and chronic phases. The analysis focused on changes in marker levels over time. Statistical methods included calculating 95% confidence intervals for each parameter.
Main Results:
At the start of the study, fibrinogen (Fg) levels were significantly elevated in MI patients compared to normal values. Levels ranged from 277 to 333 mg/dl. High molecular weight fibrinogen (HMW-Fg) was also elevated, with values between 200 and 244 mg/dl. Fibrinopeptide A (FPA) levels were elevated at 5.3 to 16.5 ng/ml. Prothrombin fragment 1+2 (F1+2) levels ranged from 1.4 to 1.8 nmol/l. Beta-thromboglobulin (beta-TG) was elevated at 110 to 118 IU/ml. Von Willebrand factor (vWF) levels were significantly higher at 139 to 195%. By 30 days, Fg and HMW-Fg returned to normal. FPA and F1+2 remained elevated throughout the study period. Beta-TG returned to normal by 120 days, and vWF by 150 days. Tissue factor (TF) and TF pathway inhibitor (TFPI) levels did not show significant changes over two years.
Conclusions:
The findings suggest that thrombin generation and activity remain elevated for up to two years after MI. The persistence of elevated FPA and F1+2 levels indicates ongoing hypercoagulability. The study supports the idea that aspirin treatment does not fully normalize coagulation activity in the long term. The authors propose that this prolonged hypercoagulable state may increase the risk of recurrent cardiovascular events. The results highlight the importance of monitoring coagulation markers beyond the acute phase. The study does not claim that aspirin is ineffective but notes its limitations in fully restoring normal coagulation. The authors emphasize the need for further research on long-term antithrombotic strategies. These findings may inform future studies on optimizing post-MI care.
Frequently Asked Questions
The study suggests that thrombin generation remains elevated for up to two years after MI, as indicated by persistent high levels of FPA and F1+2.
Fibrinogen (Fg) and high molecular weight fibrinogen (HMW-Fg) returned to normal levels by 30 days after MI.
FPA and F1+2 levels remained elevated, suggesting ongoing thrombin activity and a persistent hypercoagulable state in MI patients.
Beta-TG levels were elevated initially but returned to normal by 120 days, indicating a transient activation of platelets.
Tissue factor (TF) levels did not show statistically significant variations over the two-year period.
The findings suggest that aspirin may not fully normalize coagulation activity, indicating a need for long-term monitoring and possibly adjusted antithrombotic strategies.